JP2004500305A - ゲランゴムゲルを含む徐放性組成物 - Google Patents
ゲランゴムゲルを含む徐放性組成物 Download PDFInfo
- Publication number
- JP2004500305A JP2004500305A JP2000518698A JP2000518698A JP2004500305A JP 2004500305 A JP2004500305 A JP 2004500305A JP 2000518698 A JP2000518698 A JP 2000518698A JP 2000518698 A JP2000518698 A JP 2000518698A JP 2004500305 A JP2004500305 A JP 2004500305A
- Authority
- JP
- Japan
- Prior art keywords
- sustained release
- gellan gum
- release
- gel
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920002148 Gellan gum Polymers 0.000 title claims abstract description 48
- 239000000216 gellan gum Substances 0.000 title claims abstract description 36
- 235000010492 gellan gum Nutrition 0.000 title claims abstract description 36
- 238000013268 sustained release Methods 0.000 title claims abstract description 20
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 20
- 239000000203 mixture Substances 0.000 title claims description 22
- 239000003814 drug Substances 0.000 claims description 22
- 229940079593 drug Drugs 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 18
- 229920000642 polymer Polymers 0.000 claims description 9
- 239000011148 porous material Substances 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 5
- 239000000230 xanthan gum Substances 0.000 claims description 5
- 229920001285 xanthan gum Polymers 0.000 claims description 5
- 235000010493 xanthan gum Nutrition 0.000 claims description 5
- 229940082509 xanthan gum Drugs 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 3
- 238000005538 encapsulation Methods 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 abstract description 12
- 239000000499 gel Substances 0.000 description 76
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 26
- 239000011575 calcium Substances 0.000 description 22
- 230000000694 effects Effects 0.000 description 21
- 150000001768 cations Chemical class 0.000 description 14
- 239000012530 fluid Substances 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 11
- 229930003268 Vitamin C Natural products 0.000 description 11
- 235000019154 vitamin C Nutrition 0.000 description 11
- 239000011718 vitamin C Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 10
- 229910052791 calcium Inorganic materials 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 9
- 229960004025 sodium salicylate Drugs 0.000 description 9
- 102000009027 Albumins Human genes 0.000 description 8
- 108010088751 Albumins Proteins 0.000 description 8
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 8
- 239000008367 deionised water Substances 0.000 description 8
- 229910021641 deionized water Inorganic materials 0.000 description 8
- 229960001680 ibuprofen Drugs 0.000 description 8
- 238000011068 loading method Methods 0.000 description 8
- 239000012190 activator Substances 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 7
- 235000013305 food Nutrition 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- 102000036675 Myoglobin Human genes 0.000 description 5
- 108010062374 Myoglobin Proteins 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 125000002252 acyl group Chemical group 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000001879 gelation Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229960002009 naproxen Drugs 0.000 description 4
- 229960003940 naproxen sodium Drugs 0.000 description 4
- 230000007423 decrease Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 241001082081 Elodia Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000736131 Sphingomonas Species 0.000 description 1
- 241000790234 Sphingomonas elodea Species 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- ZNOZWUKQPJXOIG-XSBHQQIPSA-L [(2r,3s,4r,5r,6s)-6-[[(1r,3s,4r,5r,8s)-3,4-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-4-[[(1r,3r,4r,5r,8s)-8-[(2s,3r,4r,5r,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-sulfonatooxyoxan-2-yl]oxy-4-hydroxy-2,6-dioxabicyclo[3.2.1]octan-3-yl]oxy]-5-hydroxy-2-( Chemical compound O[C@@H]1[C@@H](O)[C@@H](OS([O-])(=O)=O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H]2OC[C@H]1O[C@H](O[C@H]1[C@H]([C@@H](CO)O[C@@H](O[C@@H]3[C@@H]4OC[C@H]3O[C@H](O)[C@@H]4O)[C@@H]1O)OS([O-])(=O)=O)[C@@H]2O ZNOZWUKQPJXOIG-XSBHQQIPSA-L 0.000 description 1
- 238000010564 aerobic fermentation Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000013627 low molecular weight specie Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000004161 plant tissue culture Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6382297P | 1997-10-31 | 1997-10-31 | |
| PCT/US1998/023093 WO1999022768A1 (en) | 1997-10-31 | 1998-10-30 | Controlled release compositions comprising gellan gum gels |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004500305A true JP2004500305A (ja) | 2004-01-08 |
| JP2004500305A5 JP2004500305A5 (enExample) | 2005-01-06 |
Family
ID=22051739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000518698A Pending JP2004500305A (ja) | 1997-10-31 | 1998-10-30 | ゲランゴムゲルを含む徐放性組成物 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1027072A1 (enExample) |
| JP (1) | JP2004500305A (enExample) |
| AU (1) | AU744328B2 (enExample) |
| CA (1) | CA2308291A1 (enExample) |
| WO (1) | WO1999022768A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7943925B2 (en) | 2003-03-17 | 2011-05-17 | Semiconductor Energy Laboratory Co., Ltd. | Light emitting element and light emitting device |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1646367A4 (en) * | 2003-07-21 | 2011-06-15 | Nesher Solutions Ltd | ORAL DOSAGE FORMS WITH CONTROLLED RELEASE ON GELLAN RUBBER BASE A NEW PLATFORM TECHNOLOGY FOR MAGNETIC RETENTION |
| WO2012037117A1 (en) | 2010-09-13 | 2012-03-22 | Bev-Rx, Inc. | Aqueous drug delivery system comprising off - flavor masking agent |
| US9132291B2 (en) | 2010-10-05 | 2015-09-15 | Dfb Technology, Ltd. | Water-in-oil emulsion compositions containing gellan gum for topical delivery of active ingredients to the skin or mucosa |
| ITUB20156821A1 (it) * | 2015-12-09 | 2017-06-09 | Altergon Sa | CAPSULE DI GELATINA MOLLE A RILASCIO pH INDIPENDENTE |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4503084A (en) * | 1983-05-31 | 1985-03-05 | Merck & Co., Inc. | Non-heated gellan gum gels |
| JPS62125850A (ja) * | 1985-11-26 | 1987-06-08 | San Ei Chem Ind Ltd | 球状ゲルの製法 |
| JPS63267361A (ja) * | 1987-04-24 | 1988-11-04 | San Ei Chem Ind Ltd | 賦香等性ゲル状物 |
| GB2219803A (en) * | 1988-06-20 | 1989-12-20 | Merck & Co Inc | Gellan/K-carrageenan/mannan blends |
| GB9414966D0 (en) * | 1994-07-26 | 1994-09-14 | Danbiosyst Uk | Pharmaceutical compositions for the nasal administration of antiviral agents |
| US5879712A (en) * | 1995-06-07 | 1999-03-09 | Sri International | Method for producing drug-loaded microparticles and an ICAM-1 dosage form so produced |
| JP3774975B2 (ja) * | 1997-02-25 | 2006-05-17 | 大正製薬株式会社 | ゲル状徐放性組成物 |
-
1998
- 1998-10-30 WO PCT/US1998/023093 patent/WO1999022768A1/en not_active Ceased
- 1998-10-30 AU AU12921/99A patent/AU744328B2/en not_active Ceased
- 1998-10-30 EP EP98956386A patent/EP1027072A1/en not_active Withdrawn
- 1998-10-30 JP JP2000518698A patent/JP2004500305A/ja active Pending
- 1998-10-30 CA CA002308291A patent/CA2308291A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7943925B2 (en) | 2003-03-17 | 2011-05-17 | Semiconductor Energy Laboratory Co., Ltd. | Light emitting element and light emitting device |
Also Published As
| Publication number | Publication date |
|---|---|
| AU1292199A (en) | 1999-05-24 |
| EP1027072A1 (en) | 2000-08-16 |
| WO1999022768A1 (en) | 1999-05-14 |
| CA2308291A1 (en) | 1999-05-14 |
| AU744328B2 (en) | 2002-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10668013B2 (en) | Chewable gelled emulsions | |
| JP2594486B2 (ja) | 局所的眼薬組成物 | |
| JP4880657B2 (ja) | 粘膜表面への改良された薬物供給 | |
| EP1990045B1 (en) | Polysaccharide capsules and methods of preparation | |
| AU2015360580A1 (en) | Linear polysaccharide based film products | |
| US20180000743A1 (en) | Modified Alginate Hydrogels for Therapeutic Agents, their Preparation and Methods Thereof | |
| EP3335732B1 (en) | Water-soluble films comprising low-viscosity alginates | |
| EP3386489B1 (en) | Soft gelatin capsules with ph-independent release | |
| EP1765299B1 (en) | Process for formulating fast dispersing dosage forms comprising at least one fish gelatin selected on the basis of molecular weight | |
| JP2004099558A (ja) | 医薬用ゼリー組成物 | |
| JP2010536810A (ja) | 水及び有効成分含有ゲル | |
| AU744328B2 (en) | Controlled release compositions comprising gellan gum gels | |
| Sekar et al. | Characterization and formulation of miswak film for the treatment of chronic periodontitis: An in vitro study | |
| CN121443268A (zh) | 药物制剂 | |
| JP2001508411A (ja) | 生物学的活性成分の経口投与のための潤滑性自立型（インタクト）ゲル | |
| Das et al. | Gellan gum–based microparticles and beads for sustained drug delivery | |
| CN104640537A (zh) | 用于口服剂型的低熔点丙酸衍生物粒子 | |
| WO2013046161A1 (en) | Topical pharmaceutical compositions comprising acyclovir | |
| JPH04243819A (ja) | 徐放性製剤 | |
| JP2017214299A (ja) | 半固形製剤及びその製造方法 | |
| RU2306938C1 (ru) | Способ профилактики и лечения воспалительных заболеваний полостных органов размножения у животных | |
| RU2273480C2 (ru) | Фармацевтическая композиция для лечения заболеваний микробной и паразитарной этиологии | |
| JPH0672109B2 (ja) | 徐放性錠剤 | |
| ATE390122T1 (de) | Universelle zusammensetzung zur kontrollierten wirkstofffreigabe enthaltend xanthangummi und natriumalginat | |
| MXPA99005003A (en) | Lubricious self-standing (intact) gel for oral delivery of biologically-active ingredients |